Postoperative hypertension is a sign before it is a number
Postoperative hypertension is a sign to be explained before it is a number to be treated, because its common causes are reversible bedside findings and no evidence sets a general pressure at which treatment must begin.
Consensus only · rests on expert consensusmechanism establishedclinical claim untested
A high blood pressure in the PACU is one of the commonest reasons a nurse calls a resident, and the commonest response is to treat the number. The sources on this day say the number has no evidence-based threshold. The POQI statement on perioperative arterial pressure records that, for adult noncardiac surgical patients, there is insufficient evidence to recommend a general upper limit at which therapy should be initiated, although pressures above 160 mmHg have been associated with myocardial injury and infarction sessler-2019-d6. That is the strongest available statement that the number itself is not the treatment target.
The consequence of getting this wrong is a patient whose pain, full bladder or rising carbon dioxide is treated with a vasodilator. The pressure falls and the cause remains.
Mechanism
Blood pressure rises after surgery when the sympathetic nervous system is driven by something. In the PACU the drivers are mostly ordinary and mostly reversible: pain, a distended bladder, hypercarbia from hypoventilation, hypoxemia, shivering and cold, anxiety, and the abrupt withdrawal of an antihypertensive the patient takes at home. Each raises catecholamine output, heart rate and vascular tone. A vasodilator lowers the pressure by acting on the last step in that chain; it does nothing to the first. The mechanism therefore dictates the sequence: find what is driving the sympathetic response and remove it, and treat the pressure directly only when nothing reversible explains it or the level itself threatens harm.
Evidence
The POQI consensus statement is the primary source. For adult noncardiac surgical patients it finds insufficient evidence to recommend a general upper limit of arterial pressure at which therapy should be initiated, while recording that pressures above 160 mmHg have been associated with myocardial injury and infarction sessler-2019-d6.
The 2013 ASA guideline on postanesthetic care states that the literature continues to be insufficient to evaluate the impact of cardiovascular assessment and monitoring, or of routine electrocardiographic monitoring, on perioperative complications asa-pacu-2013-d6.
The agents a PACU stocks for this do have labels, and two of them do not say what residents are commonly taught. Labetalol’s label gives an initial 20 mg by slow intravenous injection over 2 min, then further injections of 40 or 80 mg at 10-minute intervals until the pressure responds or a total of 300 mg has been given; by continuous infusion the effective dose is usually 50 to 200 mg fda-labetalol-label-2020. Hydralazine’s usual injected dose is 20 to 40 mg, repeated as necessary, with the pressure beginning to fall within a few minutes and the average maximal decrease at 10 to 80 min; its label warns that where intracranial pressure is raised, lowering the blood pressure may increase cerebral ischemia fda-hydralazine-label-2021. Nicardipine, labelled for short-term treatment of hypertension when oral therapy is not feasible, starts at 5 mg/hr and increases by 2.5 mg/hr every 15 min to a maximum of 15 mg/hr fda-nicardipine-label-2024. Clevidipine starts at 1 to 2 mg/hr, may be doubled at 90-second intervals early, usually achieves its effect at 4 to 6 mg/hr, and is capped by its lipid load at no more than 1000 mL or an average of 21 mg/hr in 24 h; patients on a prolonged infusion who are not transitioned to another agent should be watched for rebound hypertension for at least 8 h after it stops fda-clevidipine-label-2022.
None of that is outcome evidence. These are labelled doses for treating a blood pressure, in a day whose whole argument is that no source establishes the pressure at which treating one helps.
What this does not show
Neither source tests any treatment of postoperative hypertension against any outcome. The POQI document is a consensus statement and the ASA document is a guideline that describes its own literature as insufficient sessler-2019-d6asa-pacu-2013-d6. The association above 160 mmHg is an association, and the statement that draws attention to it declines, in the same sentence, to turn it into a threshold sessler-2019-d6.
The differential itself, pain, bladder distension, hypercarbia, hypoxemia and drug withdrawal, is clinical reasoning that the held sources support only in part: the bladder limb is in the ASA guideline, and the rest is physiology asa-pacu-2013-d6. The withdrawal limb has one sourced member. The clonidine label warns that sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma, more likely after higher doses or with a beta-blocker, with rare hypertensive encephalopathy, stroke and death, and it instructs that clonidine be continued to within four hours of surgery and resumed as soon as possible afterwards fda-clonidine-label-2022. Two limits on that: the sentence above is paraphrased past its first clause and has not been re-quoted word for word from the label, and no source here covers withdrawal of any other antihypertensive class.
This day has two ledger rows, both consensus documents, and no primary study. It is the thinnest day with sources on the site, and the topic term it carries was added to the vocabulary for it.
The beta-blocker question this page lost content over now has an answer, and the answer is newer than the version usually quoted. The 2024 perioperative cardiovascular guideline makes it a Class 1 recommendation, on moderate-quality non-randomized evidence, that beta blockers be continued through the perioperative period in patients already on stable doses, as appropriate to the clinical circumstances thompson-2024-accaha. Two neighbouring recommendations belong with it, because together they are the teaching point. A new indication for beta blockade should be started far enough ahead of elective surgery, optimally more than 7 days, to allow tolerability to be assessed and the dose titrated, which is a weak recommendation. And beta blockers should not be started on the day of surgery in a patient with no immediate need, which is graded as harm on randomized evidence thompson-2024-accaha. The predecessor guideline said the same thing more bluntly, that beta blockers should be continued in patients who have been on them chronically; the current wording adds both the stable-dose condition and the clinical-circumstances qualifier, and the softening is the part worth teaching fleisher-2014.
A note on how that was read, because it changed. The wording above now comes from the journal’s own recommendation table, read on 2026-09-08 under institutional access. The table renders as an image with no alternative text, which is why the article’s text appeared to skip its own recommendations, and it was transcribed by eye. Two things are still owed. The article carries a published correction that nobody on this project has read, so if the correction touches the beta-blocker section this wording may need revisiting. And the page number was never confirmed, because the online version carries none.
At the bedside
When the pressure is high, examine the patient before you examine the drug chart. Ask about pain and look at the analgesia given. Palpate or scan the bladder. Look at the respiratory rate and depth, the capnograph if there is one, and the saturation. Check the temperature and whether the patient is shivering. Ask what antihypertensives they take at home and when the last dose was.
Treat what you find. A pressure that falls when the pain is treated or the bladder is emptied was never a hypertension problem.
If nothing reversible explains it and the level is one you judge dangerous for this patient, then treat the pressure, knowing that no general threshold has evidence behind it and that the number above which injury has been associated is 160 mmHg sessler-2019-d6. Local practice differs. the pressure at which a PACU protocol calls for direct treatment, and the agent used, differ between institutions; follow local protocol and know that the threshold is a local decision, not an evidence-based one.
Sources
Every number above carries its ledger key. Each key below resolves to the source record.
Sessler DI, Bloomstone JA, Aronson S, et al. Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019 May;122(5):563-574.
Consensus statement 2, verbatim sense: for adult noncardiac surgical patients there is insufficient evidence to recommend a general upper limit of arterial pressure at which therapy should be initiated, although pressures above 160 mmHg have been associated with myocardial injury and infarction. This is the strongest available statement that the number itself is not the treatment target.
American Society of Anesthesiologists Task Force on Postanesthetic Care. Practice Guidelines for Postanesthetic Care: an updated report. Anesthesiology. 2013 Feb;118(2):291-307.
States that the literature continues to be insufficient to evaluate the impact of cardiovascular assessment and monitoring, or of routine electrocardiographic monitoring, on perioperative complications. Also states that assessment of urine output and voiding should be done case by case, which is the bladder limb of this day's differential.
Clonidine Hydrochloride Tablets, USP [prescribing information]. Solco Healthcare US / Major Pharmaceuticals. Revised 07/2022. DailyMed set ID 8171776a-dd14-4dcc-8860-3c27d8ea9504.
FDA label, WARNINGS (withdrawal): 'Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma' (first 125 characters verbatim; remainder paraphrased in findings - re-quote from label); reactions more likely after higher doses or with beta-blockers; rare hypertensive encephalopathy, stroke, death; taper over 2-4 days. PRECAUTIONS (perioperative): continue to within four hours of surgery and resume as soon as possible thereafter.
Labetalol Hydrochloride Injection, USP [prescribing information]. Hikma Pharmaceuticals USA Inc. Revised January 2020. DailyMed set ID 30f9fdef-8781-4327-9a8d-812cb31ff041. DailyMed updated 10 July 2024.
FDA label, DOSAGE AND ADMINISTRATION, Repeated Intravenous Injection, VERBATIM: 'Initially, labetalol HCl injection should be given in a 20 mg dose (which corresponds to 0.25 mg/kg for an 80 kg patient) by slow intravenous injection over a 2 minute period.' And: 'Immediately before the injection and at 5 and 10 minutes after injection, supine blood pressure should be measured to evaluate response. Additional injections of 40 or 80 mg can be given at 10 minute intervals until a desired supine blood pressure is achieved or a total of 300 mg of labetalol HCl injection has been injected. The maximum effect usually occurs within 5 minutes of each injection.' Slow Continuous Infusion, VERBATIM: 'The diluted solution should be administered at a rate of 2 mL/min to deliver 2 mg/min' and 'The effective intravenous dose is usually in the range of 50 to 200 mg. A total dose of up to 300 mg may be required in some patients.' No boxed warning on this label. NOTE FOR THE CARD: the label's 20 mg initial dose is larger than the 5 to 10 mg increments the hypertension card currently teaches; the card's figure has no label source.
Hydralazine Hydrochloride Injection, USP [prescribing information]. Akorn, Inc. Revision code HY00N Rev. 04/21. DailyMed set ID e31239e0-8c5a-4d10-9404-af32278484a3. DailyMed updated 12 September 2022.
FDA label, DOSAGE AND ADMINISTRATION, VERBATIM: 'When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine hydrochloride injection should be used only when the drug cannot be given orally. The usual dose is 20 to 40 mg, repeated as necessary.' And: 'Blood pressure should be checked frequently. It may begin to fall within a few minutes after injection, with the average maximal decrease occurring in 10 to 80 minutes. In cases where there has been increased intracranial pressure, lowering the blood pressure may increase cerebral ischemia.' No boxed warning on this label. NOTE FOR THE CARD: the label's usual dose is 20 to 40 mg, not the 5 to 10 mg the hypertension card currently teaches.
Nicardipine Hydrochloride Injection, USP, for intravenous use [prescribing information]. Hikma Pharmaceuticals USA Inc. Revised 8/2024. DailyMed set ID 18fb1c2b-0c1e-436c-a5b6-d4840b5da228. DailyMed updated 24 August 2024.
FDA label section 1.1, VERBATIM: 'Nicardipine hydrochloride injection, USP is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable.' Dosing, VERBATIM: 'For a gradual reduction in blood pressure, initiate therapy at a rate of 5 mg/hr. If desired blood pressure reduction is not achieved at this dose, increase the infusion rate by 2.5 mg/hr every 15 minutes up to a maximum of 15 mg/hr, until desired blood pressure reduction is achieved. For more rapid blood pressure reduction, titrate every 5 minutes.' Section 2.1, VERBATIM: 'Administer Nicardipine Hydrochloride by slow continuous infusion by a central line or through a large peripheral vein. Change the infusion site every 12 hours if administered via peripheral vein.' Section 2.5, on hypotension or tachycardia, VERBATIM: 'discontinue infusion. When blood pressure and heart rate stabilize, restart infusion at low doses such as 30 mL/hr to 50 mL/hr (3 mg/hr to 5 mg/hr) and titrate to maintain desired blood pressure.' No boxed warning on this label.
CLEVIPREX (clevidipine) injectable emulsion [prescribing information]. Chiesi USA, Inc. Revised 9/2022. DailyMed set ID f9290625-b723-4eda-bab8-a97bef6041f6. DailyMed updated 6 November 2025.
FDA label section 2.2, VERBATIM: 'Initiate the intravenous infusion of Cleviprex at 1-2 mg/hour.' And: 'The dose may be doubled at short (90 second) intervals initially. As the blood pressure approaches goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. An approximately 1-2 mg/hour increase will generally produce an additional 2-4 mmHg decrease in systolic pressure.' And: 'The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Patients with severe hypertension may require doses up to 32 mg/hour, but there is limited experience at this dose rate.' Lipid-load limit, VERBATIM: 'Because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Cleviprex infusion is recommended per 24 hour period.' Section 2.1, VERBATIM: 'Patients who receive prolonged Cleviprex infusions and are not transitioned to other antihypertensive therapies should be monitored for the possibility of rebound hypertension for at least 8 hours after the infusion is stopped.' No boxed warning on this label. Note: the DailyMed product title prints the drug name as 'clevipidine', a typographical error in the label title.
Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR, Ahmad FS, Allen RB, Altin SE, Auerbach A, Berger JS, Chow B, Dakik HA, Eisenstein EL, Gerhard-Herman M, Ghadimi K, Kachulis B, Leclerc J, Lee CS, Macaulay TE, Mates G, Merli GJ, Parwani P, Poole JE, Rich MW, Ruetzler K, Stain SC, Sweitzer B, Talbot AW, Vallabhajosyula S, Whittle J, Williams KA. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. Circulation. 2024;150(19):e351-e442.
ANSWERS THE DAY 6 / HYPERTENSION CARD BETA-BLOCKER QUESTION. Section 7.7 Perioperative Beta Blockers, COR 1, LOE B-NR, VERBATIM: 'In patients on stable doses of beta blockers undergoing NCS, beta blockers should be continued through the perioperative period as appropriate based on the clinical circumstances.' Adjacent, COR 2b LOE B-NR: 'In patients scheduled for elective NCS who have a new indication for beta blockade, beta blockers may be initiated far enough before surgery (optimally >7 days) to permit assessments of tolerability and drug titration if needed.' And COR 3 Harm, LOE B-R: 'In patients undergoing NCS and with no immediate need for beta blockers, beta blockers should not be initiated on the day of surgery due to increased risk for postoperative mortality.' ROUTE CAVEAT THAT MUST BE RESOLVED BEFORE THIS IS QUOTED AS VERBATIM FROM THE JOURNAL: the Circulation article page loaded and is marked Free Access, but its section 7.7 body text was truncated out of what the fetcher returned. The quoted text above was read from the AHA's own official slide set for this guideline on professional.heart.org, which reproduces the recommendation tables with COR and LOE. That is an AHA publication but it is not the journal article. One confirmatory read of Circulation page e399 is recommended.
Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN. 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol. 2014;64(22):e77-e137.
PREDECESSOR ROW, kept only to show what changed. Class I recommendation, VERBATIM: 'Beta blockers should be continued in patients undergoing surgery who have been on beta blockers chronically.' Level of Evidence returned as B with an 'SR' annotation, which in that document marks recommendations supported by its commissioned systematic review; how the SR tag is typeset on the printed page could not be confirmed, so treat the LOE as B with the SR annotation uncertain. The 2024 ACC/AHA guideline is the current version and its wording differs, adding 'on stable doses' and 'as appropriate based on the clinical circumstances'.
Three items. Every option carries an explanation. Progress is not saved.
Progress is not saved. Answers live on this page only and are gone when you
leave it. There are no accounts and nothing is recorded.
Item 1 of 3 · basic · ABA-BASIC, ITE, nursing
What does the POQI consensus statement on perioperative arterial pressure say about a general upper limit at which treatment of hypertension should begin in adult noncardiac surgical patients?
There is no evidence-based ceiling; the association above a level is not the same as a treatment threshold.
Item 2 of 3 · advanced · ABA-ADVANCED, ITE, nursing
A patient in the PACU is hypertensive and tachycardic thirty minutes after arrival. Which action comes first?
Explain the number before you treat it; most causes in the PACU are found by examination.
Item 3 of 3 · basic · ABA-BASIC, ITE
What does the 2013 ASA postanesthetic care guideline say about cardiovascular assessment and routine electrocardiographic monitoring during recovery?
The guideline cannot say that routine cardiovascular monitoring changes complications.